Welcome to Alitair Pharmaceuticals, Inc.

Alitair is a specialty pharmaceutical company with a focus on the respiratory space. Currently, we are developing two Orphan drugs for bronchiectasis. We expect to begin clinical trials for both compounds within the next 6 months.

We also have products under development for Rx and OTC cough treatment.  Our lead cough candidate is a solid oral dosage form of benzonatate which is protected by a composition of matter patent.

Alitair currently has four issued patents and we anticipate expanding our patent portfolio further in the near future.

This e-mail address is being protected from spambots. You need JavaScript enabled to view it for more information about our Orphan drug candidates and for our cough licensing opportunities.


Alitair

 

 
Solution Managers